Skip to main content

Advertisement

An experimental Alzheimer's drug outperforms one just approved by the FDA

03:37

July 17, 2023

Jon Hamilton

The image shows amyloid plaques in the brains of three patients in the early stages of Alzheimer's. Those plaques are greatly reduced in the first two patients, who got donanemab, but remain unchanged in a patient who received no treatment. (Eli Lilly and Company)

Related:

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow
Having an out-of-body experience? Blame this sausage-shaped piece of your brain
An Alzheimer's drug is on the way, but getting it may still be tough. Here's why
Huntington's spreads like 'fire in the brain.' Scientists say they've found the spark

Advertisement

Advertisement